{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T04:02:25Z","timestamp":1789790545445,"version":"4.0.1"},"reference-count":107,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Clin Med&amp;#65533;Insights&amp;#65533;Reprod&amp;#65533;Health"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>Women pre- or post-menopause and living with obesity are at an increased risk of obesity-related complications such as polycystic ovary syndrome, infertility, cardiovascular disease, and breast and uterine cancers. Previously, it has been demonstrated that a clinically meaningful weight loss of \u22655% of total body weight can have benefits for women living with gynecological conditions related to obesity and can improve the symptoms of polycystic ovary syndrome, improve fertility, and reduce the risk of gynecological and breast cancers. In this review article, we provide an overview of the impact of obesity on women\u2019s health and evaluate the current pharmacological treatment landscape for weight management, with particular emphasis on incretin-based therapies, as relevant treatment options for obstetrician-gynecologists and gynecologists treating women at an increased risk of obesity-related complications. Literature searches were conducted using PubMed to identify articles published between 2015 and 2026, with the search date range subsequently expanded to articles published within the last 30 years. English language and adult only were specified in the filters for the search criteria, as was publication type (narrative reviews, systematic reviews, and randomized controlled trials were included). Searches were also conducted without any filters. With glucagon-like peptide-1 receptor agonists established as effective weight-management tools, obstetrician-gynecologists and gynecologists can offer evidence-based treatment options to women with obesity-related complications as an addition to lifestyle interventions (such as a reduced-calorie diet and increased physical activity) to aid weight loss. Obstetrician-gynecologists and gynecologists are ideally placed to diagnose and treat obesity in women who present with obesity-related gynecological complications. We hope that the clinical data presented, and the practical tips shared in this review, encourage obstetrician-gynecologists and gynecologists to initiate weight-loss conversations in everyday clinical practice to support women in achieving clinically meaningful weight loss and improve outcomes in women with obesity-related complications.<\/jats:p>","DOI":"10.1177\/26334941261481473","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:39:06Z","timestamp":1789493946000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["The clinical relevance of obesity and glucagon-like peptide-1-based therapies for chronic weight management in patients treated by obstetrician-gynecologists and gynecologists: A non-systematic narrative review"],"prefix":"10.1177","volume":"20","author":[{"given":"Suzanne","family":"Mackey","sequence":"first","affiliation":[{"name":"Salv\u00e9o Weight Management"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Egan","sequence":"additional","affiliation":[{"name":"true. Women\u2019s Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3577-4009","authenticated-orcid":false,"given":"Karen","family":"Elkind-Hirsch","sequence":"additional","affiliation":[{"name":"Dexcom Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"e_1_3_5_2_2","unstructured":"World Health Organization. World Obesity Atlas. https:\/\/www.worldobesity.org\/resources\/resource-library\/world-obesity-atlas-2022 (2022) accessed 19 June 2026."},{"key":"e_1_3_5_3_2","unstructured":"US Centers for Disease Control and Prevention. Prevalence of Obesity and Severe Obesity Among Adults: United States 2017\u20132018. https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db360.htm#:\u223c:text=Key_findings Data_from_the&text=In_2017%E2%80%932018%2C_the_age in_women_than_in_men (2018) accessed 19 June 2026."},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.191707"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2020.8683"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-020-0548-0"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-025-01447-3"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10081989"},{"key":"e_1_3_5_9_2","volume-title":"Women\u2019s Preventive Services Guidelines","author":"Health Resources and Services Administration","year":"2025","unstructured":"Health Resources and Services Administration. Women\u2019s Preventive Services Guidelines, 2025. https:\/\/www.hrsa.gov\/womens-guidelines (accessed 2026 15 June."},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.3003"},{"key":"e_1_3_5_11_2","unstructured":"Food & Drug Administration. XENICAL (orlistat) capsules. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2003\/20766se5-018_xenical_lbl.pdf (2003) accessed 19 June 2026."},{"key":"e_1_3_5_12_2","unstructured":"Food & Drug Administration. QSYMIA (phentermine and topiramate extended-release capsules) for oral use CIV. Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/022580s021lbl.pdf (2022) accessed 19 June 2026."},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.5534\/wjmh.200010"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41367-019-0009-1"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.116.003497"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dms030"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/09513590.2017.1391209"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-018-0336-z"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0787-1"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.4638"},{"key":"e_1_3_5_21_2","unstructured":"World Cancer Research Fund. Diet nutrition physical activity and endometrial cancer. 2018. https:\/\/www.wcrf.org\/wp-content\/uploads\/2021\/02\/Endometrial-cancer-report.pdf (accessed 19 June 2026)."},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr1606602"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1191093"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.951186"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2021.12.012"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP161365.GL"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.5822"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000001792"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz226"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jand.2015.04.022"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S008"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21358"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3415"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-062288"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12384"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2021.12.003"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/2042018814559725"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.2337\/ds16-0026"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.538"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1089\/met.2018.0088"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00155"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13230"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2018.1435129"},{"key":"e_1_3_5_44_2","volume-title":"WEGOVY (semaglutide) injection, for subcutaneous use; WEGOVY (semaglutide) tablets, for oral use","author":"Novo Nordisk","year":"2026","unstructured":"Novo Nordisk. WEGOVY (semaglutide) injection, for subcutaneous use; WEGOVY (semaglutide) tablets, for oral use. Prescribing Information, 2026. https:\/\/www.novo-pi.com\/wegovy.pdf, accessed 19 June 2026."},{"key":"e_1_3_5_45_2","volume-title":"OZEMPIC\u00ae (semaglutide) injection, for subcutaneous use","author":"Novo Nordisk","year":"2017","unstructured":"Novo Nordisk. OZEMPIC\u00ae (semaglutide) injection, for subcutaneous use. Prescribing information, 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209637lbl.pdf, accessed 19 June 2026."},{"key":"e_1_3_5_46_2","volume-title":"ADLYXIN\u00ae (lixisenatide) injection, for subcutaneous use","author":"Sanofi-Aventis","year":"2016","unstructured":"Sanofi-Aventis. ADLYXIN\u00ae (lixisenatide) injection, for subcutaneous use. Prescribing information, 2016. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208471orig1s000lbl.pdf, accessed 19 June 2026."},{"key":"e_1_3_5_47_2","volume-title":"SAXENDA\u00ae (liraglutide) injection, for subcutaneous use","author":"Novo Nordisk","year":"2014","unstructured":"Novo Nordisk. SAXENDA\u00ae (liraglutide) injection, for subcutaneous use. Prescribing information, 2014. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206321orig1s000lbl.pdf, accessed 2 June 2026."},{"key":"e_1_3_5_48_2","volume-title":"VICTOZA\u00ae (liraglutide) injection, for subcutaneous use","author":"Novo Nordisk","year":"2010","unstructured":"Novo Nordisk. VICTOZA\u00ae (liraglutide) injection, for subcutaneous use. Prescribing information, 2010. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/022341s027lbl.pdf, accessed 19 June 2026."},{"key":"e_1_3_5_49_2","volume-title":"RYBELSUS\u00ae (semaglutide) tablets, for oral use","author":"Novo Nordisk","year":"2017","unstructured":"Novo Nordisk. RYBELSUS\u00ae (semaglutide) tablets, for oral use. Prescribing information, 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/213051s000lbl.pdf, accessed 19 June 2026."},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411892"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30069-7"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.9676"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.120"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2016.52"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22726"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1745"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22462"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13399"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.07.017"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1831"},{"key":"e_1_3_5_62_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02026-4"},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00008-0"},{"key":"e_1_3_5_64_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23619"},{"key":"e_1_3_5_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00225-6"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00226-8"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.08.022"},{"key":"e_1_3_5_69_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2500969"},{"key":"e_1_3_5_71_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_3_5_72_2","doi-asserted-by":"publisher","DOI":"10.1002\/pdi.2051"},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2013.149"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.927859"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa891"},{"key":"e_1_3_5_76_2","unstructured":"Eli Lilly and Company. ZEPBOUND\u2122 (tirzepatide) injection for subcutaneous use: highlights of prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/217806s000lbl.pdf (2023) accessed 19 June 2026."},{"key":"e_1_3_5_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01200-X"},{"key":"e_1_3_5_78_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_3_5_79_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02597-w"},{"key":"e_1_3_5_80_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.24945"},{"key":"e_1_3_5_81_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02883-1"},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2416394"},{"key":"e_1_3_5_83_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505928"},{"key":"e_1_3_5_84_2","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24254"},{"issue":"2","key":"e_1_3_5_85_2","first-page":"11","article-title":"How to use GLP-1 receptor agonist therapy safely and effectively","volume":"25","author":"Milne N","year":"2023","unstructured":"Milne N. How to use GLP-1 receptor agonist therapy safely and effectively. Prim Care Diabetes 2023; 25(2): 11\u201313.","journal-title":"Prim Care Diabetes"},{"key":"e_1_3_5_86_2","unstructured":"ClinicalTrials.gov. A study to evaluate the safety of exposure to Wegovy during pregnancy. 2023. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05503927 (accessed 19 June 2026)."},{"key":"e_1_3_5_87_2","volume-title":"MOUNJARO (tirzepatide) injection, for subcutaneous use","author":"Eli Lilly and Company","year":"2025","unstructured":"Eli Lilly and Company. MOUNJARO (tirzepatide) injection, for subcutaneous use. Prescribing Information, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215866s039lbl.pdf, accessed 19 June 2026."},{"key":"e_1_3_5_88_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.1.155"},{"key":"e_1_3_5_89_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2011.330"},{"key":"e_1_3_5_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60205-5"},{"key":"e_1_3_5_91_2","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.111.024927"},{"key":"e_1_3_5_92_2","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20309"},{"key":"e_1_3_5_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60888-4"},{"key":"e_1_3_5_94_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0234"},{"key":"e_1_3_5_95_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2010.147"},{"key":"e_1_3_5_96_2","unstructured":"Piccinini-Valli H Adamo K Bell R et al. Weight management over the reproductive years for adult women with obesity. https:\/\/obesitycanada.ca\/guidelines\/reproductive\/ (2020) accessed 15 June 2026."},{"key":"e_1_3_5_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2018.12.001"},{"key":"e_1_3_5_98_2","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.338"},{"key":"e_1_3_5_99_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014533"},{"key":"e_1_3_5_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2022.04.027"},{"key":"e_1_3_5_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2017.08.012"},{"key":"e_1_3_5_102_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-021-00441-1"},{"issue":"7","key":"e_1_3_5_103_2","first-page":"506","article-title":"The 5 As framework for obesity management: do we need a more intricate model?","volume":"63","author":"Sturgiss E","year":"2017","unstructured":"Sturgiss E, van Weel C. The 5 As framework for obesity management: do we need a more intricate model? Can Fam Physician 2017; 63(7): 506\u2013508.","journal-title":"Can Fam Physician"},{"key":"e_1_3_5_104_2","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22581"},{"key":"e_1_3_5_105_2","doi-asserted-by":"publisher","DOI":"10.3109\/13697137.2012.707385"},{"key":"e_1_3_5_106_2","doi-asserted-by":"publisher","DOI":"10.3390\/nu11051136"},{"key":"e_1_3_5_107_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjsports-2017-097608"},{"key":"e_1_3_5_108_2","unstructured":"American Society of Anesthesiologists. American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. https:\/\/www.asahq.org\/about-asa\/newsroom\/news-releases\/2023\/06\/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative (2023) accessed 19 June 2026."}],"container-title":["Therapeutic Advances in Reproductive Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/26334941261481473","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/26334941261481473","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/26334941261481473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:17:19Z","timestamp":1789787839000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/26334941261481473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":107,"alternative-id":["10.1177\/26334941261481473"],"URL":"https:\/\/doi.org\/10.1177\/26334941261481473","relation":{},"ISSN":["2633-4941","2633-4941"],"issn-type":[{"value":"2633-4941","type":"print"},{"value":"2633-4941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"26334941261481473"}}